Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4430] to SMN/Gemin 1
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
Product nameAnti-SMN/Gemin 1 antibody [EPR4430]
See all SMN/Gemin 1 primary antibodies
DescriptionRabbit monoclonal [EPR4430] to SMN/Gemin 1
Tested applicationsSuitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt or ICC
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human SMN/Gemin 1 aa 150-250. The exact sequence is proprietary.
- Recombinant Human SMN/Gemin 1 protein (ab114802) can be used as a positive control in WB. HeLa, HepG2, K562 cell lysates
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab108424 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 32 kDa.|
|IHC-P||1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionThe SMN complex plays an essential role in spliceosomal snRNP assembly in the cytoplasm and is required for pre-mRNA splicing in the nucleus. It may also play a role in the metabolism of snoRNPs.
Tissue specificityExpressed in a wide variety of tissues. Expressed at high levels in brain, kidney and liver, moderate levels in skeletal and cardiac muscle, and low levels in fibroblasts and lymphocytes. Also seen at high levels in spinal cord. Present in osteoclasts and mononuclear cells (at protein level).
Involvement in diseaseDefects in SMN1 are the cause of spinal muscular atrophy autosomal recessive type 1 (SMA1) [MIM:253300]. Spinal muscular atrophy refers to a group of neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.
Defects in SMN1 are the cause of spinal muscular atrophy autosomal recessive type 2 (SMA2) [MIM:253550]. SMA2 is an autosomal recessive spinal muscular atrophy of intermediate severity, with onset between 6 and 18 months. Patients do not reach the motor milestone of standing, and survive into adulthood.
Defects in SMN1 are the cause of spinal muscular atrophy autosomal recessive type 3 (SMA3) [MIM:253400]. SMA3 is an autosomal recessive spinal muscular atrophy with onset after 18 months. SMA3 patients develop ability to stand and walk and survive into adulthood.
Defects in SMN1 are the cause of spinal muscular atrophy autosomal recessive type 4 (SMA4) [MIM:271150]. SMA4 is an autosomal recessive spinal muscular atrophy characterized by symmetric proximal muscle weakness with onset in adulthood and slow disease progression. SMA4 patients can stand and walk.
Sequence similaritiesBelongs to the SMN family.
Contains 1 Tudor domain.
Cellular localizationCytoplasm. Nucleus > gem. Localized in subnuclear structures next to coiled bodies, called Gemini of Cajal bodies.
- Information by UniProt
- BCD541 antibody
- Component of gems 1 antibody
- Gemin 1 antibody
All lanes : Anti-SMN/Gemin 1 antibody [EPR4430] (ab108424) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : HepG2 cell lysate
Lane 3 : K562 cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 32 kDa
ab108424 staining Gemin 1 in paraffin-embedded Human kidney tissue by Immunohistochemistry at dilution of 1:500.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab108424 has been referenced in 9 publications.
- Qin R et al. Mst1 deletion reduces hyperglycemia-mediated vascular dysfunction via attenuating mitochondrial fission and modulating the JNK signaling pathway. J Cell Physiol 235:294-303 (2020). PubMed: 31206688
- Ding H et al. Upregulation of miR-101a Suppresses Chronic Renal Fibrosis by Regulating KDM3A via Blockade of the YAP-TGF-ß-Smad Signaling Pathway. Mol Ther Nucleic Acids 19:1276-1289 (2020). PubMed: 32092824
- Wang Y et al. ANXA3 Silencing Ameliorates Intracranial Aneurysm via Inhibition of the JNK Signaling Pathway. Mol Ther Nucleic Acids 17:540-550 (2019). PubMed: 31362241
- Qian X et al. Survival Motor Neuron (SMN) Protein Insufficiency Exacerbates Renal Ischemia/Reperfusion Injury. Front Physiol 10:559 (2019). PubMed: 31139093
- Yao MY et al. microRNA-328 in exosomes derived from M2 macrophages exerts a promotive effect on the progression of pulmonary fibrosis via FAM13A in a rat model. Exp Mol Med 51:63 (2019). PubMed: 31164635
- Ramos DM et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest 129:4817-4831 (2019). PubMed: 31589162
- Zhang Z et al. LncRNA HOTAIR mediates TGF-ß2-induced cell growth and epithelial-mesenchymal transition in human lens epithelial cells. Acta Biochim Biophys Sin (Shanghai) 50:1028-1037 (2018). PubMed: 30239553
- Yu B et al. MicroRNA-124 suppresses growth and aggressiveness of osteosarcoma and inhibits TGF-ß-mediated AKT/GSK-3ß/SNAIL-1 signaling. Mol Med Rep 17:6736-6744 (2018). PubMed: 29488603
- Wang J et al. MicroRNA-485 Modulates the TGF-ß/ Smads Signaling Pathway in Chronic Asthmatic Mice by Targeting Smurf2. Cell Physiol Biochem 51:692-710 (2018). PubMed: 30463065